Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treat… Read more
Atrium Therapeutics, Inc. Common Stock (RNA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.101x
Based on the latest financial reports, Atrium Therapeutics, Inc. Common Stock (RNA) has a cash flow conversion efficiency ratio of -0.101x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-169.77 Million) by net assets ($1.69 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Atrium Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Atrium Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Atrium Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atrium Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AG MORTG.INV.NEW DL-01
F:8AGA
|
N/A |
|
Jasmine International Public Company Limited
PINK:JASUF
|
0.595x |
|
Tianjin LVYIN Landscape and Ecology Construction Co Ltd
SHE:002887
|
0.001x |
|
ABG Sundal Collier Holding ASA
PINK:ABGSF
|
-0.176x |
|
Shanghai Huaming Intelligent Terminal Equipment Co Ltd
SHE:300462
|
0.028x |
|
Clearwater Paper Corporation
NYSE:CLW
|
0.006x |
|
Advanced Ceramic X
TWO:3152
|
0.017x |
|
QORIA Ltd
AU:QOR
|
-0.050x |
Annual Cash Flow Conversion Efficiency for Atrium Therapeutics, Inc. Common Stock (2018–2025)
The table below shows the annual cash flow conversion efficiency of Atrium Therapeutics, Inc. Common Stock from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.69 Billion | $-650.44 Million | -0.385x | -82.43% |
| 2024-12-31 | $1.42 Billion | $-300.87 Million | -0.211x | +11.20% |
| 2023-12-31 | $500.76 Million | $-119.06 Million | -0.238x | -0.86% |
| 2022-12-31 | $578.08 Million | $-136.27 Million | -0.236x | +5.17% |
| 2021-12-31 | $381.43 Million | $-94.81 Million | -0.249x | -105.08% |
| 2020-12-31 | $306.22 Million | $-37.12 Million | -0.121x | -218.15% |
| 2019-12-31 | $-65.36 Million | $2.49 Million | -0.038x | -116.23% |
| 2018-12-31 | $-41.13 Million | $-9.65 Million | 0.235x | -- |